Chronic breathlessness is a distressing and highly prevalent symptom of advanced chronic respiratory diseases. It is associated with social isolation, high healthcare costs and poor prognosis. Currently, there are few effective drug treatments thus, chronic breathlessness represents a huge unmet need.
Over two days, this conference brings together experts, researchers, people affected by breathlessness, policymakers, the public and healthcare professionals from around the world.
Through engaging presentations and interactive discussions, discover the treatment options for refractory breathlessness, a distressing symptom that affects individuals with various respiratory conditions, as well as the ethical aspects of carrying out an international, multi-centre, randomised controlled trial of a drug for this condition (BETTER-B).
Don't miss this unique opportunity to connect with leading experts in the field. Whether you're a healthcare professional, researcher, policymaker, person affected by breathlessness or simply interested in the topic.
Better Treatments for Refractory Breathlessness project (BETTER-B) is an international, multicentre, randomised controlled trial testing the effectiveness of mirtazapine, an established antidepressant, in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease. Find out more.
This event is being organised by ARC palliative and end of life care researchers based at the Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King's College London.